DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03707171

CompletedPhase 3

Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

30

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Changes of cognitive function

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03707171
Org study IDLiraglutide

Timeline

Milestones

Study start2018-10-01actual
Study first posted2018-10-16actual
Primary completion2019-02-01actual
Study completion2019-05-01actual
Last update posted2019-07-10actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetes。

Exclusion criteria

•Type 2 diabetes with acute diabetic complications.
•Type 1 diabetes.
•Other diseases affecting cognitive function (congenital dementia,brain trauma,severe heart dysfunction,severe kidney dysfunction,severe lung dysfunction,epilepsy,severe hypoglycemic coma,cerebrovascular disease,ischemic heart disease,etc).
•Alcohol abuse,mental illness and psychoactive substance abuse.
•History of thyroid disease.
•Any surgical or medical conditions that significantly influence absorption, distribution, metabolism or excretion of the intervention drugs.

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
4
Cardiometabolic biomarkers
3
Glycemic / diabetes
2
MASH / liver
1
Renal / kidney
1
Other clinical outcomes
1

Weight & body composition

4 endpoints
Secondary/protocol endpoint

Change of Body mass index(BMI)

Time frame:Baseline,4weeks,8weeks，12weeks(End of Trial)

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Change of waist circumference

Time frame:Baseline,4weeks,8weeks，12weeks(End of Trial)

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Change of hip circumference

Time frame:Baseline,4weeks,8weeks，12weeks(End of Trial)

change from baseline, improvement

Secondary/protocol endpoint

Change of waist-to-hip ratio

Time frame:Baseline,4weeks,8weeks，12weeks(End of Trial)

change from baseline, improvement

Glycemic / diabetes

2 endpoints
Secondary/protocol endpoint

Change of fasting plasma glucose

Time frame:Baseline,4weeks,8weeks，12weeks(End of Trial)

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change of HbA1c

Time frame:Baseline,4weeks,8weeks，12weeks(End of Trial)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

MASH / liver

1 endpoint
Secondary/protocol endpoint

Change of liver enzymes

Time frame:Baseline,4weeks,8weeks，12weeks(End of Trial)

change from baseline, improvement

Renal / kidney

1 endpoint
Secondary/protocol endpoint

Change of kidney function

Time frame:Baseline,4weeks,8weeks，12weeks(End of Trial)

eGFR, change

change from baseline, improvement

LOINC 98979-8

Cardiometabolic biomarkers

3 endpoints
Secondary/protocol endpoint

Changes of systolic blood pressure and diastolic blood pressure

Time frame:Baseline,4weeks,8weeks，12weeks(End of Trial)

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change of lipid profile

Time frame:Baseline,4weeks,8weeks，12weeks(End of Trial)

change from baseline, improvement

componentsTotal cholesterol, change, HDL-C, change, LDL-C, change, Triglycerides, change

Secondary/protocol endpoint

Change of CRP

Time frame:Baseline,4weeks,8weeks，12weeks(End of Trial)

change from baseline, improvement

Other clinical outcomes

1 endpoint
Primary/protocol endpoint

Changes of cognitive function assessed by cognitive function scale after 12 weeks.

Time frame:Baseline,4weeks,8weeks，12weeks(End of Trial)

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.